Publication Highlights

Clinical approach to evaluating incidentally discovered adrenal adenomas

Anand Vaidya, Amir Hamrahian, Irina Bancos, Maria Fleseriu, Hans K. Ghayee, on behalf of the AACE Pituitary, Gonad, Adrenal, and Neuroendocrine Disease State Network. The evaluation of incidentally discovered adrenal masses. Endocr Pract. 2019;25(2):178-192.

The prevalence of incidentally discovered adrenal adenomas has grown substantially in recent years due to an increase in cross-sectional imaging. Clinicians are faced with the challenge of evaluating these adrenal masses to prevent future health hazards and risks. Incorrect or insufficient evaluation of adrenal adenomas could put patients at an increased risk for preventable adverse cardiometabolic outcomes. Therefore, the American Association of Clinical Endocrinologists developed a Disease State Clinical Review to simplify the general approach to incidentally discovered adrenal masses with a case-based overview that builds on previous guidelines and consensus statements. Although not formal guidelines, these recommendations provide clinicians with a practical approach to the evaluation of incidentally discovered adrenal masses.

There are 2 fundamental questions that clinicians are faced with when discovering an adrenal mass:

1 Does the adrenal adenoma represent a malignancy?

2 Is there evidence of clinically significant adrenal hormone excess (eg, hypercortisolism)?


Clinicians should consider biochemical screening for adrenal hormone excess, even if radiographic characteristics suggest that the adrenal mass is benign. In most scenarios, patients do not display the typical signs of overt syndromes of hormone excess, such as Cushing syndrome. However, clinicians may still uncover hormone excess upon biochemical evaluation.

The following additional questions may arise in certain patient situations:

Would a biopsy be useful in the diagnosis, management, and prognosis of the adrenal mass?

Is medical treatment or surgery warranted?

Could long-term surveillance of the adrenal mass, including biochemical testing and imaging, be useful? If so, for how long and at what frequency?

Managing incidentally discovered adrenal masses

a simplified clinical algorithm

incidentally discovered adrenal masses clinical algorithm CT=computed tomography; FDG-PET=fluorodeoxyglucose-positron emission tomography; HU=Hounsfield units; MRI=magnetic resonance imaging.
Based on information from Vaidya et al., Endocr Pract. 2019.

Guidelines for biochemical testing of adrenal hormone excess in patients with incidentally discovered adrenal mass

Suspected diagnosis

Autonomous cortisol secretion

Primary aldosteronism

Pheochromocytoma

Adrenal androgen excess

Who to test

Autonomous cortisol secretion

All patients

Primary aldosteronism

Patients with high blood pressure and/or low potassium

Pheochromocytoma

Patients whose imaging shows lipid-poor, contrast-avid, heterogeneous adrenal lesions

Adrenal androgen excess

Patients with abnormal hair growth, symptoms suggestive of virilization

Evaluation

Autonomous cortisol secretion

1-mg overnight dexamethasone suppression test

Primary aldosteronism

Serum ARR

Pheochromocytoma

Plasma (or urinary) fractionated metanephrines

Adrenal androgen excess

DHEAS total testosterone

Abnormal result

Autonomous cortisol secretion

Nonfunctional:
≤1.8 μg/dL

Possibly functional:
1.9-5.0 μg/dL

Autonomous hypercortisolism:
>5.0 μg/dL

Primary aldosteronism

Suppressed ARR >20-30

Pheochromocytoma

Greater than 2 to 4 times higher than the upper limit of the reference range

Adrenal androgen excess

Higher than the upper limit of the reference range

ARR=aldosterone-to-renin ratio; DHEAS=dehydroepiandrosterone sulfate.
Based on information from Vaidya et al., Endocr Pract. 2019.
  • The late-night salivary cortisol test and the 1-mg overnight dexamethasone suppression test (DST) are the most sensitive tests for detecting subtle forms of autonomous cortisol secretion and nonphysiologic cortisol secretion
  • DST may be repeated after a few months to evaluate for consistently elevated cortisol levels
  • The 24-hour urinary-free cortisol test is frequently normal in mild autonomous cortisol excess

All patients with adrenal masses are usually recommended for screening with 1-mg DST.

  • Despite a lack of classical features suggestive of Cushing syndrome during physical examination, biochemical testing may detect autonomous hypercortisolism
  • Even mild or autonomous hypercortisolism can increase the risk for future cardiometabolic and skeletal concerns
  • A 1-mg DST is the recommended initial test for hypercortisolism, where morning cortisol levels ≤1.8 μg/dL are considered “normal”
  • The prevalence of autonomous hypercortisolism with incidentally discovered adrenal masses has been reported as approximately 5% among more than 2,000 patients from 13 different studies; however, milder degrees of hypercortisolism may exist in a much higher percentage of individuals with adrenal tumors
  • The collective results may indicate a possible benefit for the treatment of hypercortisolism if:
    • Multiple lines of biochemical evidence suggest autonomous, adrenocorticotropic hormone-independent hypercortisolism, and
    • Clinical evidence associated with cortisol excess (fragility fractures, dyslipidemia, and type 2 diabetes) exists